BGB324 With Pembrolizumab or Dabrafenib/Trametinib in Melanoma

Oddbjørn Straume, MD, PhD, associate professor, department of Clinical Science, Haukeland University Hospital, discusses a study investigating BGB324 with pembrolizumab or dabrafenib/trametinib in patients with advanced non-resectable or metastatic melanoma.